Clinical Trial Update: An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adjuvant nivolumab vs placebo after surgical resection for bladder cancer and upper tract urothelial carcinoma, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Upper Tract Urothelial Carcinoma

Drugs mentioned

• OPDIVO (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Various Advanced Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-12-01